DirectSync Surgical
Private Company
Funding information not available
Overview
DirectSync Surgical is developing a novel platform for smart, self-powered orthopedic implants that sense load and stimulate bone growth using energy harvested from human motion. Founded in 2019, the San Diego-based company has secured FDA Breakthrough Device Designation and significant non-dilutive NIH SBIR funding, validating its innovative approach. The technology aims to improve surgical outcomes by providing real-time post-operative data to physicians while actively promoting healing, positioning the company at the intersection of medtech and digital health. It is currently in the pre-clinical stage and seeking seed investment to advance its platform.
Technology Platform
Proprietary biomaterial and implant design that harvests energy from human motion to power integrated sensors for load monitoring and deliver DC electrical stimulation to enhance bone healing, eliminating the need for batteries or external devices.
Opportunities
Risk Factors
Competitive Landscape
Competition includes large incumbent orthopedic companies (e.g., Medtronic, Stryker) selling traditional implants and separate bone growth stimulators, as well as emerging companies developing smart sensor implants (often battery-powered). DirectSync's key differentiation is the integrated, motion-powered combination of stimulation and sensing without batteries.